<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2400">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04353128</url>
  </required_header>
  <id_info>
    <org_study_id>MeCOVID</org_study_id>
    <nct_id>NCT04353128</nct_id>
  </id_info>
  <brief_title>Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.</brief_title>
  <acronym>MeCOVID</acronym>
  <official_title>Multicenter Randomized Controlled Trial of the Efficacy of Melatonin in the Prophylaxis of SARS-coronavirus-2 Infection Among High Risk Contacts.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigación Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is an urgent need to evaluate interventions that can prevent the infection with
      SARS-CoV 2 of healthcare workers at risk. Melatonin is an inexpensive and safe product with
      protective effect in both bacterial and viral infections likely due to its anti-inflammatory
      and anti-oxidative effects. This randomized controlled trial seeks to evaluate is efficacy as
      a prophylaxis in healthcare workers exposed to the virus in their clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthcare workers are at an increased risk of acquiring COVID-19 due to an increased
      exposure to the virus and global personal protective equipment shortages. Preventing the
      infection of healthcare workers is critical the current epidemic situation when healthcare
      systems are under extreme pressure. There is a lack of evidence surrounding potential
      preventive strategies to decrease the incidence of COVID-19 among healthcare workers.

      Melatonin, an endogenous hormone involved in circadian rhythm control, is an inexpensive and
      safe product that has shown protective effects in bacterial and viral infections likely due
      to its anti-inflammatory and anti-oxidative effects.

      SARS-CoV 2 seems to relatively spare younger children and those who are infected develop the
      severe forms of the disease very rarely. Peak melatonin serum levels are higher in younger
      children and decrease with age. These levels are also higher in women, specially during
      pregnancy, who also seem to be less affected by the virus when compared to men.

      The investigators hypothesize that elevating peak melatonin levels to a range similar to that
      of children by administering 2 mg of melatonin daily might prevent the infection with
      SARS-CoV 2 among exposed healthcare workers. The investigators also hypothesize that among
      those who develop the disease melatonin might prevent the more severe forms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-CoV 2 infection rate</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Number of confirmed (positive CRP) symptomatic infections in each treatment group</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV 2</condition>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg of melatonin orally before bedtime for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identically looking placebo orally before bedtime for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin 2mg</intervention_name>
    <description>2 mg of prolonged release melatonin tablets per os (P.O.) before bedtime for 12 weeks</description>
    <arm_group_label>Melatonin</arm_group_label>
    <other_name>circadin 2 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Identically looking placebo tablets P.O. before bedtime for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthcare workers from the public and private Spanish hospital network at risk of
             SARS-CoV 2 infection

          -  Not having a previous COVID19 diagnosis

          -  Not having experienced COVID19 symptoms from March 1st 2020 until randomization

          -  Understanding the purpose of the trial and not having taken any pre-exposure
             prophylaxis (PrEP) including HIV PrEP from March 1st 2020 until randomization

          -  Having a negative SARS-CoV 2 CRP before randomization

          -  Having a negative urinary pregnancy test in the previous 7 days for premenopausal
             women

          -  Premenopausal women and males with premenopausal couples must commit to using a high
             efficiency anticonceptive method

        Exclusion Criteria:

          -  HIV infection

          -  Active hepatitis B infection

          -  Renal failure (CrCl &lt; 60 mL/min/1.73 m2) or need for hemodialysis

          -  Osteoporosis

          -  Myasthenia gravis

          -  Retinitis pigmentosa

          -  Bradycardia (less than 50 bpm)

          -  Weight less than 40 Kg

          -  Treatment with drugs that prolong the QT interval for more than 7 days in the last
             month before randomization including: azithromycin, cisapride, methadone, droperidol,
             sotalol, quinidine, clarithromycin, haloperidol...

          -  Hereditary intolerance to galactose, Lapp lactase deficiency or glucose or galactose
             malabsorption

          -  Treatment with fluvoxamine

          -  Treatment with benzodiazepines or benzodiazepine analogues such as zolpidem, zopiclone
             or zaleplon

          -  Pregnancy

          -  Breastfeeding

          -  History of potentially immune derived diseases such as: lupus, Crohn's disease,
             ulcerative colitis, vasculitis or rheumatoid arthritis

          -  Insulin-dependent diabetes mellitus

          -  Known history of hypersensitivity to the study drug or any of its components

          -  Patients that should not be included in the study at the judgment of the research team
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro de la Oliva, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio J Carcas</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irene García García</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amelia Rodríguez Mariblanca</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lucía Martínez de Soto</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María J Rosales</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José R Arribas</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan González</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto M Borobia, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Rodriguez-Rubio, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alberto M Borobia, MD, PhD</last_name>
    <phone>+34912071466</phone>
    <email>alberto.borobia@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Borobia, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are children less susceptible to COVID-19? J Microbiol Immunol Infect. 2020 Jun;53(3):371-372. doi: 10.1016/j.jmii.2020.02.011. Epub 2020 Feb 25.</citation>
    <PMID>32147409</PMID>
  </reference>
  <reference>
    <citation>Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, Zhang W, Wang Y, Bao S, Li Y, Wu C, Liu H, Liu D, Shao J, Peng X, Yang Y, Liu Z, Xiang Y, Zhang F, Silva RM, Pinkerton KE, Shen K, Xiao H, Xu S, Wong GWK; Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 Infection in Children. N Engl J Med. 2020 Apr 23;382(17):1663-1665. doi: 10.1056/NEJMc2005073. Epub 2020 Mar 18.</citation>
    <PMID>32187458</PMID>
  </reference>
  <reference>
    <citation>Scholtens RM, van Munster BC, van Kempen MF, de Rooij SE. Physiological melatonin levels in healthy older people: A systematic review. J Psychosom Res. 2016 Jul;86:20-7. doi: 10.1016/j.jpsychores.2016.05.005. Epub 2016 May 10. Review.</citation>
    <PMID>27302542</PMID>
  </reference>
  <reference>
    <citation>Gunn PJ, Middleton B, Davies SK, Revell VL, Skene DJ. Sex differences in the circadian profiles of melatonin and cortisol in plasma and urine matrices under constant routine conditions. Chronobiol Int. 2016;33(1):39-50. doi: 10.3109/07420528.2015.1112396. Epub 2016 Jan 5.</citation>
    <PMID>26731571</PMID>
  </reference>
  <reference>
    <citation>Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, Liu C, Reiter RJ. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020 Jun 1;250:117583. doi: 10.1016/j.lfs.2020.117583. Epub 2020 Mar 23. Review.</citation>
    <PMID>32217117</PMID>
  </reference>
  <reference>
    <citation>Tan DX, Korkmaz A, Reiter RJ, Manchester LC. Ebola virus disease: potential use of melatonin as a treatment. J Pineal Res. 2014 Nov;57(4):381-4. doi: 10.1111/jpi.12186. Epub 2014 Oct 14. Review.</citation>
    <PMID>25262626</PMID>
  </reference>
  <reference>
    <citation>Ran L, Chen X, Wang Y, Wu W, Zhang L, Tan X. Risk Factors of Healthcare Workers with Corona Virus Disease 2019: A Retrospective Cohort Study in a Designated Hospital of Wuhan in China. Clin Infect Dis. 2020 Mar 17. pii: ciaa287. doi: 10.1093/cid/ciaa287. [Epub ahead of print]</citation>
    <PMID>32179890</PMID>
  </reference>
  <reference>
    <citation>Gooneratne NS, Edwards AY, Zhou C, Cuellar N, Grandner MA, Barrett JS. Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. J Pineal Res. 2012 May;52(4):437-45. doi: 10.1111/j.1600-079X.2011.00958.x. Epub 2012 Feb 21.</citation>
    <PMID>22348451</PMID>
  </reference>
  <reference>
    <citation>Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.</citation>
    <PMID>32091533</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melatonin</keyword>
  <keyword>prevention</keyword>
  <keyword>covid19</keyword>
  <keyword>Sars-CoV2</keyword>
  <keyword>healthcare</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

